histidine + naproxen

This is a **combination drug consisting of histidine (most notably in the form of α-fluoromethylhistidine, a histidine decarboxylase inhibitor) and naproxen (a nonsteroidal anti-inflammatory drug/NSAID)**. The combination is under investigation for its synergistic **analgesic and anti-inflammatory effects**. Naproxen inhibits cyclooxygenase (COX) enzymes, thereby decreasing prostaglandin synthesis and reducing inflammation, pain, and fever. α-fluoromethylhistidine inhibits histidine decarboxylase, leading to prolonged reduction in histamine levels in the body, which may enhance analgesia and anti-inflammatory effects when used with naproxen. The combination aims to provide superior efficacy and faster onset of action compared to either drug alone in treatment of pain and inflammatory conditions such as arthritis. Administration can be oral, topical, parenteral, by inhalation, or rectal. No approved product or unique brand for this combination is noted in public sources, but the combination (specifically α-fluoromethylhistidine + naproxen) is described in patent literature for pharmaceutical compositions[1].